Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2026.

Highlights

“Our global net revenues declined for the three months ended September 30, 2026 as compared to the same period in 2025 primarily driven by a 44% decrease in U.S. net revenues as our licensing agreement with NeoImmuneTech Inc. (NIT), became effective on May 15, 2026,” commented Willis Lee, Chairman and Chief Executive Officer of Emmaus. “The decline was partially offset by a related reduction in our operating expenses. Management believes that the conflict in the Middle East also adversely affected net revenues in the region,” he added.

Financial and Operating Results

Net Revenues. Net revenues for the three months ended September 30, 2026 were $1.9 million, compared to $3.4 million in the same period in 2025 driven by lower direct sales of Endari® following the company’s execution of the License Agreement with NIT.

Operating Expenses. Total operating expenses for the three months were $1.9 million compared to $2.4 million in the comparable period in 2025. The decrease was due primarily to decreased expenses attributable to the transfer of our sales force to NIT in connection with the license arrangement.

Income (Loss) From Operations. Loss from operations for the three months was $0.4 million compared to income from operations of $0.7 million in the same period in 2025. The changes were due to the decrease in net revenues, partially offset by lower operating expenses.

Other Expense. The company realized other expense of $4.4 million for the three months compared to $2.2 million in the same period in 2025. The increase was primarily due to change in fair value of conversion features derivative based upon an increase in the company’s stock price.

Net Loss. For the three months, the company realized a net loss of $4.7 million, or $0.07 basic loss per share based on approximately 70.2 million weighted-average common shares, compared to net loss of $2.1 million, or $0.03 basic loss per share based on approximately 63.9 million weighted-average common shares in the comparable period in 2025. The increase in net loss was attributable primarily to the decrease in net revenues and increase in other expense.

Liquidity and Capital Resources. At September 30, 2026, the company had cash and cash equivalents of $1.0 million, compared to $2.1 million at December 31, 2025.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. Endari® (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older, is approved for marketing in the United States, Israel, Kuwait, Qatar, the United Arab Emirates, Bahrain and Oman and is available on a named patient or early access basis in France, the Netherlands, and the Kingdom of Saudi Arabia, where Emmaus’ application for marketing authorization is awaiting final action by the Saudi Food & Drug Authority. For more information, please visit www.emmausmedical.com.

About Endari® (prescription grade L-glutamine oral powder)

Endari®, Emmaus’ prescription grade L-glutamine oral powder, was approved by the U.S. Food and Drug Administration (FDA) in July 2017 for treating sickle cell disease in adult and pediatric patients five years of age and older.

Indication

Endari® is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Important Safety Information

The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.

Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.

The safety and efficacy of Endari® in pediatric patients with sickle cell disease younger than five years of age has not been established.

For more information, please see full Prescribing Information of Endari® at: www.ENDARIrx.com/PI.

About Sickle Cell Disease

There are approximately 100,000 people living with sickle cell disease (SCD) in the United States and millions more globally. The sickle gene is found in every ethnic group, not just among those of African descent; and in the United States an estimated 1-in-365 African Americans and 1-in-16,300 Hispanic Americans are born with SCD.1 The genetic mutation responsible for SCD causes an individual’s red blood cells to distort into a “C” or a sickle shape, reducing their ability to transport oxygen throughout the body. These sickled red blood cells break down rapidly, become very sticky, and develop a propensity to clump together, which causes them to become stuck and cause damage within blood vessels. The result is reduced blood flow to distal organs, which leads to physical symptoms of incapacitating pain, tissue and organ damage, and early death.2

1Source: Data & Statistics on Sickle Cell Disease – National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, December 2020.

2Source: Committee on Addressing Sickle Cell Disease – A Strategic Plan and Blueprint for Action — National Academy of Sciences Press, 2020.

Forward-looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time, including doubt about the company’s ability to continue as a going concern and other factors disclosed in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 31, 2026 and Quarterly Report on Form 10-Q filed on November 18, 2026, and actual results may differ materially. Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law.

Emmaus Life Sciences, Inc.

Condensed Consolidated Statement of Operations and Comprehensive Income (Loss)

(In thousands, except share and per share amounts)

Three Months Ended September 30,

 

Nine Months Ended September 30,

2026

 

2025

 

2026

 

2025

Revenue, Net

$

1,892

 

$

3,378

 

$

10,192

 

$

8,601

 

Cost of Goods Sold

 

369

 

 

247

 

 

881

 

 

622

 

Gross Profit

 

1,523

 

 

3,131

 

 

9,311

 

 

7,979

 

Operating Expenses

 

1,892

 

 

2,436

 

 

6,712

 

 

8,634

 

Income (loss) from Operations

 

(369

)

 

695

 

 

2,599

 

 

(655

)

Net Loss

 

(4,741

)

 

(2,076

)

 

(6,737

)

 

(5,541

)

Comprehensive Loss

 

(2,476

)

 

(3,796

)

 

(5,045

)

 

(3,027

)

Net Loss per Share

$

(0.07

)

$

(0.03

)

$

(0.10

)

$

(0.09

)

Weighted Average Common Shares Outstanding

 

70,188,263

 

 

63,865,571

 

 

70,188,263

 

 

63,865,571

 

 

Emmaus Life Sciences, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

`

As of

September 30, 2026

December 31, 2025

Assets

Current Assets:

Cash and cash equivalents

$

971

 

$

2,127

 

Accounts receivable, net

 

1,516

 

 

2,804

 

Inventories, net

 

1,417

 

 

1,555

 

Prepaid expenses and other current assets

 

777

 

 

1,260

 

Total Current Assets

 

4,681

 

 

7,746

 

Property and Equipment, net

 

73

 

 

113

 

Right of use assets

 

771

 

 

766

 

Investment in convertible bond

 

10,994

 

 

12,604

 

Investment in equity security

 

989

 

 

–

 

Other Assets

 

227

 

 

207

 

Total Assets

$

17,735

 

$

21,436

 

 

Liabilities and Stockholders’ Deficit

Current Liabilities:

Accounts payable and accrued expenses

$

25,394

 

$

22,615

 

Operating lease liabilities, current portion

 

401

 

 

348

 

Conversion feature derivative, notes payable

 

3,247

 

 

–

 

Notes payable, current portion

 

11,256

 

 

11,151

 

Convertible notes payable, net of discount

 

17,309

 

 

17,380

 

Other current liabilities

 

15,279

 

 

17,578

 

Total Current Liabilities

 

72,886

 

 

69,072

 

Other long-term liabilities

 

13,501

 

 

15,972

 

Total Liabilities

 

86,387

 

 

85,044

 

Stockholders’ Deficit

 

(68,652

)

 

(63,608

)

Total Liabilities & Stockholders’ Deficit

$

17,735

 

$

21,436

 

 

Media gallery

About The Author